Bruker's new Chemical Analysis division will include the product lines it has agreed to acquire from Varian.
The sale of the three businesses satisfies conditions set forth by the European Commission as part of its conditional approval of Agilent Technologies’ purchase of Varian.
The sale of the product lines to Bruker will clear the way for Agilent to complete its $1.5 billion acquisition of Varian, which is now expected by the end of April.
Varian's Q1 revenues dipped 3 percent due to lower sales volume and lower average selling prices of certain analytical instruments products, the firm said.
The firms have yet to receive US regualtory approval for their merger.
The deal had been delayed as both the EC and the US Federal Trade Commission had questions concerning it.
The sales of certain gas chromatography product lines will satisfy the conditions for clearance of the acquisition in the EU.
A Beckman Coulter official provided an update on revenue guidance and the firm's pending molecular diagnostics system; while an Agilent executive discussed the company's pending Varian acquisition and new UHPLC system.
The EU extended its deadline to make a decision on the merger to Jan. 20.
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.